Disease Monitoring In Multiple Myeloma

The outcome for multiple myeloma (MM) patients has significantly improved in the last two decades, mainly due to the use of novel drugs with a singular mechanism of action, including immunotherapy. This has sparked a new debate about the possibility of curing a substantial proportion of MM patients which implicitly entails the need for most sensitive tools for evaluating treatment efficacy and disease monitoring (minimal residual disease –MRD) both at the BM level (next generation flow cytometry and sequencing) and outside of the BM (MRI/PET-CT, mass spectrometry)

Source: Clinical Lymphoma, Myeloma and Leukemia - January 13, 2023 Category: Hematology Authors: Jens Hillengass, Tom Martin, Noemi Puig, Bruno Paiva, Saad Usmani, Shaji Kumar, Jesus San-Miguel Tags: Commentary Source Type: research